Direxion Daily S&P Biotech Bull 3X ETF (LABU)
LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout
If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) on the same day, you are up about 235%.
34,270 Shares in Direxion Daily S&P Biotech Bull 3x Shares $LABU Purchased by JPMorgan Chase & Co.
JPMorgan Chase and Co. purchased a new stake in Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 34,270 shares of the company's stock, valued at approximately $3,208,000. JPMorgan Chase and
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Shares Gap Down – Here’s Why
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $170.74, but opened at $164.08. Direxion Daily S&P Biotech Bull 3x Shares shares last traded at $165.2680, with a volume of 83,975 shares traded. Direxion Daily S&P Biotech Bull
Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026
Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move.
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Hits New 1-Year High – What’s Next?
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $186.25 and last traded at $175.81, with a volume of 1797531 shares changing hands. The stock had previously closed at $159.31. Direxion Daily S&P
Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs
Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push toward addressing the human condition — which is often found to be shockingly frail.
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Reaches New 52-Week High – What’s Next?
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU - Get Free Report) shares hit a new 52-week high during mid-day trading on Friday. The company traded as high as $169.50 and last traded at $167.9060, with a volume of 88167 shares changing hands. The stock had previously closed at $166.04. Direxion Daily S&P Biotech
New FDA Director Could Sway Biotech ETFs
Biotech stocks could sway toward the upside with the appointment of a new director at the Federal Drug Administration's Center for Drug Evaluation and Research. Dr. Richard Pazdur will take the reigns, bringing 26 years of related industry experience.
As M&A Deals Rise, Can Biotech Pharma Break Loose?
After a relatively sluggish 2024 for mergers & acquisitions (M&A) activity in the biopharma sector, the environment could be more conducive for deals in the rest of 2025. The industry, like the rest of the capital markets, will be keeping an eye on interest rates as monetary easing by the U.S.
Buy LABU: Biotech Sector Benefits From Lower Interest Rates And AI
Seeking Alpha Quant rates LABU as a “HOLD”, but I rate it as a “BUY”. Markets expect the first interest rate cut at the September Fed meeting. LABU has strong momentum and benefits from lower interest rates.
The 3 Best Leveraged ETFs for April 2024
While there are many ways to gamble in the equities sector, targeting the best leveraged ETFs for April could be a recipe for success. To be sure, you're going to have to accept a heightened risk profile.
LABU: A Really Bad Drift
Leveraged ETFs have a non-linear, unpredictable behavior. Here is a drift dashboard with 22 leveraged ETFs. Direxion Daily S&P Biotech Bull 3X Shares ETF is the worst. LABU is an instrument for seasoned traders with planned entry and exit signals. Without a tested strategy and daily monitoring, it is an accident waiting to happen.
Early IPO Activity Could Spell Bullishness for Biotech Industry
Since the end of October 2023, the S&P 500 Biotechnology Select Industry Index jumped over 30%. It could maintain its upward trajectory given the early IPO activity in 2024 thus far.
5 Leveraged ETFs That Are Up More Than 50% in December
The demand for leveraged ETFs have increased as investors seek to register big gains in a short span.
LABU: Buy As The Biotech Sector Starts A New Bull Market (Technical Analysis)
Seeking Alpha Quant rates LABU as a strong Sell, but I rates it as a Buy due to bullish market conditions. LABU is a leveraged ETF that seeks to track 3x the daily performance of the S&P Biotechnology Select Industry Index. I believe LABU has strong momentum and is outperforming the broad market, making it a favorable investment.
LABU: Tool For Swing Traders
The Direxion Daily S&P Biotech Bull and Bear 3X Shares (LABU) provides 3x daily exposure to a biotechnology index. Levered ETFs like LABU are designed for short-term trading and may suffer tracking errors from positive convexity and volatility decay. LABU can be used as a swing trading tool for experienced traders, taking advantage of positive convexity and macro tailwinds in biotech stocks.
Top Performing Leveraged/Inverse ETFs: 12/03/2023
These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Best Inverse/Leveraged ETFs of Last Week
Wall Street was upbeat last week. The reason behind the market rally was cooling inflation.
LABU And LABD: Another Attractive Double-Short Pairs Trade
Pairing Direxion Daily's S&P Biotech Bull 3X Shares ETF with their S&P Biotech Bear 3X Shares ETF produces a low volatility couple. Shorting both assets is attractive because leveraged assets erode over time due to their higher beta and inability to stay correlated over longer timeframes. The performance of the couple is dependent on the behavior of the underlying, with the short couple expected to lose value during strong trends.
LABU: A Levered ETF Doomed From The Start
The Direxion Daily S&P Biotech Bull 3x Shares ETF (LABU) is a high-risk, leveraged ETF that aims to yield three times the performance of the S&P Biotechnology Select Industry Index. The biotech sector is known for its volatility, which can significantly impact the performance of LABU. Trading LABU is challenging due to the unpredictable nature of the biotech sector and the path dependence of leveraged ETFs. Investors should use caution and consider alternative investment options.